publication date: May. 25, 2018

Finasteride does not increase risk of prostate cancer death, PCPT results show

Finasteride, a common hormone-blocking drug, reduces men’s risk of getting prostate cancer without increasing their risk of dying from the disease, according to long-term follow-up data.

Initial study findings suggested there may be a link between use of the drug and a more lethal form of prostate cancer, but results from the Prostate Cancer Prevention Trial prove otherwise, 25 years after it opened for enrollment, according to the Southwest Oncology Group.

Ian Thompson, Jr., principal investigator of SWOG’s PCPT, delivered the findings May 19 at the Journal of Urology Lecture at the 2018 Annual American Urological Association Meeting in San Francisco.

“What we can now say is that finasteride not only significantly reduces a man’s risk of prostate cancer, it is safe to use based on very long-term follow-up in our study,” Thompson, chair of SWOG’s genitourinary cancer committee, said in a statement. “In PCPT, we found no increased risk of prostate cancer death in men who took finasteride compared with men who did not.

“These results are transformational. Prostate cancer is the most common cancer diagnosed in American men, and we have found an inexpensive, effective drug that can prevent it. I’m pleased to report that we’ve answered the questions and closed the book.”

Thompson oversees development of all urologic cancer studies for the federally-funded cancer clinical trials group, and serves as president of CHRISTUS Santa Rosa Hospital—Medical Center in San Antonio and as emeritus professor at the University of Texas Health Science Center.

Thompson and his team had set out to determine whether finasteride, a drug used to treat symptoms of prostate enlargement as well as … Continue reading Finasteride does not increase risk of prostate cancer death, PCPT results show

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2019 The Cancer Letter Inc.